期刊文献+

盐酸曲美他嗪对应用表阿霉素患者的cTnI、CRP、LVEF的影响 被引量:4

The effect of trimetazidine on cTnI, CRP, LVEF of patients received 4'epi-doxorubicin
下载PDF
导出
摘要 目的探讨曲美他嗪(TMZ)对应用表阿霉素(EPI)后患者的心肌保护作用。方法应用EPI后1个月内出现心肌受损的患者42例,随机分为盐酸曲美他嗪组(治疗组)和对照组,比较2组1个月后血清肌钙蛋白I(cTnI)、G-反应蛋白(CRP)及左室射血分数(LVEF)的变化。结果治疗组和对照组患者治疗后cTnI分别为[(0.57±0.07)mg/L vs(1.12±0.08)mg/L],CRP浓度分别为[(4.9±1.2)mg/L vs (8.8±4.2)mg/L];LVEF分别为[(52±3)% vs(41±2)%],2组比较差异有统计学意义(P<0.05)。结论TMZ可明显改善应用EPI后患者的心功能,抑制cTnI和CRP浓度的升高。 Objective To investigate the protective effect of trimetazidine(TMZ) on myocardium in patients received 4' epi-doxorubicin (EPI). Methods 42 patients whose myocardium were damaged because of the administration of EPI were randomly divided into two groups. 21 patients in treatment group received TMZ, the other 21 patients were in control group. After 1-month the changes of cardiac troponin Ⅰ( cTnⅠ), C-reactive protein (CRP) and left ventricle ejective fraction(LVEF) were observed and compared between two groups. Results After treatment the levels of cTnI in treatment group and control group were[ (0.57 ± 0.07)mg/L vs (1.12 ± 0.08)mg/L], the levels of CRP were [ (4.9 ± 1.2)mg/L vs (8.8 ± 4.2)mg/L] respectively, there were significantly decreases in these parameters between two groups( P 〈 0.05). At the same time, patients' cardiac systolic function was improved [ LVEF, (52 ± 3 ) % vs (41 ± 2) % ], there was significant differences bet ween the two groups( P 〈 0.05). Conclusion TMZ can improve cardiac function and reduce the serum levels of cTnI and CRP in patients received EPI.
出处 《疑难病杂志》 CAS 2008年第1期27-29,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 曲美他嗪 表阿霉素 肌钙蛋白Ⅰ C-反应蛋白 左室射血分数 Trimetazidine 4' epi-doxorubicin Cardiac troportin Ⅰ C-reactive protein Left ventricle ejective fraction
  • 相关文献

参考文献8

  • 1徐叔云.中华临床药物学[M].北京:人民卫生出版社,2003.78.
  • 2Swain SM,Whaley FS,Ewer MS.Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trails[J].Cancer.2003,97:2 869-2 879.
  • 3Yeh ET,Tong AT,Lenihan DJ,et al.Cardiovascular complications of cancer therapy diagnosis,pathogenesis,and management[J].Criculation.2004,109:3 122-3 131.
  • 4Dazzi H,Kaudmann K,Follath F.Anthracycline-induced acute cardiotoxicity in adults treatd for leukemia.Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukemia at the University Hospital of Zurich,Switzerland,between 1990 and 1996[J].Ann Oncol,2000,12(7):963-966.
  • 5Richardson DR,Persson L,Xu X.Molecular pharmacology of the interaction of anthracyclines with iron[J].Mol Pharmacol,2005,9:466.
  • 6Bertinchant JP,Polge A,Robert E,et al.Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiom yopathy rats,and their relationship with echocardiographic and histological findings[J].Clin Chem Acta.2003,329(1-2):39-51.
  • 7Mohammad GI,Al-Menshawy AM,Abd El-Hakeem EE,et al.The value of biochemical markers in evaluation of myocardial damage in children[J].Eng J Anaesth,2003,19(1):1-8.
  • 8Napoli PD,Taccardi AA,Barsotti A.Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy[J].Heart,2005,91(2):161-165.

共引文献100

同被引文献74

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部